



13 March 2020

ASX ANNOUNCEMENT

Director Retirement

Brisbane, Australia – ImpediMed Limited (ASX: IPD) today advises Mr Gary Goetzke has resigned from the Board effective immediately. Mr Goetzke is leaving to pursue another business opportunity in Japan.

ImpediMed Limited Chairman, Scott Ward, thanked Mr Goetzke for his significant contribution over the past three and a half years to the Company and wishes him well in his future endeavours.

In resigning, Mr Goetzke stated, "it has been my distinct pleasure to have served on the ImpediMed board over these past three plus years. I have great confidence in ImpediMed's technology, as the company strives to establish SOZO as a proven and accepted means for the early detection of lymphoedema and a measure for fluid status of those who are living with heart failure."

Authorised for release by:

Scott Ward
Chairman

Contact Details

Investor Relations Contact:

Mike Bassett, ImpediMed
T : +61 407 431 432
E: mbassett@impedimed.com

Media Contact:

Kyahn Williamson, WE Buchan
T: +61 3 9866 4722
E: kwilliamson@we-worldwide.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, protein calorie malnutrition and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.